(Press-News.org) Bowel cancer patients whose tumors contain defects in specific DNA repair systems are much less likely to experience tumour recurrence post surgery, results from a major clinical study have demonstrated.
Scientists who collaborated on the 10 year QUASAR randomised control trial, one of the largest UK clinical trials to test the benefits of chemotherapy in post-surgery bowel cancer patients, have confirmed that colon tumors containing defects in their DNA mismatch repair system are 50 percent less likely to recur following surgery compared to tumors where DNA mismatch repair is normal.
The study also suggests that patients with tumors showing mutation of the KRAS gene are more likely to re-grow compared to tumors containing a normal KRAS gene irrespective of disease stage or whether chemotherapy is administered.
These results, published in the Journal of Clinical Oncology, strongly support the introduction of DNA mismatch repair testing into routine clinical practice within the NHS. The results also highlight the possible role of KRAS mutation testing to guide use of adjuvant chemotherapy in bowel cancer patients.
Stored tumour tissue from 1913 patients enrolled in QUASAR, a clinical trial in which participants were randomised between fluorouracil/folinic acid chemotherapy or observation alone, was used for the study.
Retrospective testing of the QUASAR material was undertaken to specifically investigate the clinical value of testing for defective DNA damage repair and mutations of the BRAF and KRAS genes in order to predict tumor recurrence and sensitivity to chemotherapy in bowel cancer patients.
The study was funded by Yorkshire Cancer Research, the UK Medical Research Council and Cancer Research UK. All scientific work was performed at the University of Leeds by pathologist Dr Gordon Hutchins and PhD student Katie Southward with the analysis carried out at the University of Birmingham.
The study lead, Yorkshire Cancer Research Centenary Professor of Pathology, Phil Quirke, based at the University of Leeds, said the report confirmed the value of these molecular markers in selecting treatment strategies for non-metastatic bowel cancer patients following surgery.
"Biomarkers have radically changed the management of breast cancer with stratification of women by oestrogen receptor, progesterone receptor and HER-2 status being an integral part of therapeutic decision making," said Professor Quirke.
"Yet despite bowel cancer being almost as common as breast cancer with one million new cases occurring worldwide each year, evidence to support the routine testing of post-surgery non-metastatic bowel cancer patients with putative biomarkers, such as those for defective mismatch repair, remains elusive.
"There is still uncertainty, for example, whether the modest benefits of chemotherapy in locally advanced colorectal cancer where the tumor has not spread to the lymph nodes, (stage II disease), are sufficient to justify the toxicity, cost and inconvenience of the treatment. In this situation the selection of patients who are most likely to benefit from therapy remains problematic.
"Currently we assess the probability that a patient's tumor will recur through thorough and detailed, but often subjective, pathological assessment. The supplementation of this approach with objective, quality assured biomarkers in patients with bowel cancer could accurately predict the likelihood of recurrence and allow us to aggressively treat only those patients whose tumors are much more likely to return, sparing a significant proportion of bowel cancer patients needless chemotherapy.
"Many biomarkers have been suggested but none have so far been sufficiently validated for routine clinical application mainly because previous studies have been too small to be convincing and lacked a randomised control group.
"This new data provides unequivocal support for calls to routinely test for defective DNA damage repair in bowel cancer patients, a testing strategy that is an inexpensive and technically simple procedure. The results of this study also support further evaluation of BRAF and KRAS gene mutations to predict tumor recurrence," he said.
###
Editors Notes:
1. One of the UK's largest medical, health and bioscience research bases, the University of Leeds delivers world leading research in medical engineering, cancer, cardiovascular studies, epidemiology, molecular genetics, musculoskeletal medicine, dentistry, psychology and applied health. Treatments and initiatives developed in Leeds are transforming the lives of people worldwide with conditions such as diabetes, HIV, tuberculosis and malaria. www.leeds.ac.uk
2. Harrogate-based Yorkshire Cancer Research (YCR), the UK's largest regional medical research charity, funds around £7m a year of internationally recognised cancer research at its five centres of excellence at the universities of Bradford, Hull, Leeds, Sheffield and York and their associated teaching hospitals.
The 200 plus scientists and clinicians, funded by Yorkshire Cancer Research are among the world leaders in the fight against cancer and the charity has committed a further £15 million over the next few years to continue funding them in their effort to find a cure for all forms of cancer.
Yorkshire Cancer Research has been funding research solely in Yorkshire since 1925 and over the last 86 years it has helped generate some major medical breakthroughs enabling international cancer specialists to build upon research emanating from the region.
Over the next 10 years, Yorkshire Cancer Research is committed to slashing current statistics that show 259 people die every week from cancer in Yorkshire alone.
Yorkshire Cancer Research is the most cost efficient cancer research charity in the UK spending 83 pence in every pound on cancer research.
Donations to Yorkshire Cancer Research keep the very best doctors and clinicians working in Yorkshire ensuring Yorkshire people, who get cancer, have the best possible chance to survive.
Yorkshire Cancer Research is a registered charity. Registered charity number 516898.
To donate Text 'Yorkshire' to 70007. Each text costs £3, and a minimum of £1.90 will go to Yorkshire Cancer Research. Alternatively donate online www.yorkshirecancerresearch.org.uk
New bowel cancer evidence calls for routine DNA repair test
2011-03-09
ELSE PRESS RELEASES FROM THIS DATE:
Malaria's weakest link
2011-03-09
A group of researchers from EPFL's Global Health Institute (GHI) and Inserm (Institut National de la Santé et de la Recherche Médicale, the French government agency for biomedical research) has discovered that a class of chemotherapy drugs originally designed to inhibit key signaling pathways in cancer cells also kills the parasite that causes malaria. The discovery could quickly open up a whole new strategy for combating this deadly disease.
The research, published online in the journal Cellular Microbiology, shows that the malaria parasite depends upon a signaling pathway ...
Study: Homeless patients cost $2,500 more than the average patient for each hospital stay
2011-03-09
TORONTO, ON., March 8, 2011—Homeless patients cost about $2,500 more per hospital stay than the average patient, according to a new study by researchers at St. Michael's Hospital.
Homeless people with medical or surgical problems arrive at the hospital with underlying health issues and stay longer than others, often because there is no place to send them after their initial medical crisis has been treated, the study found. Those with psychiatric illness arrive at the hospital much sicker than others.
The findings suggest the cost of hospitalizing people who are homeless ...
Extremely fast MRAM data storage within reach
2011-03-09
This release is available in German.
Magnetic Random Access Memories (MRAM) are the most important new modules on the market of computer storage devices. Like the well known USB-sticks, they store information into static memory, but MRAM offer short access times and unlimited writing properties. Commercial MRAMs have been on the market since 2005. They are, however, still slower than the competitors they have among the volatile storage media. An invention made by the Physikalisch-Technische Bundesanstalt (PTB) changes this situation: A special chip connection, in association ...
How can robots get our attention?
2011-03-09
Getting someone's attention can be easy with a loud noise or a shout, but what if the situation calls for a little more tact? How can a robot use subtle cues to attract a human's notice and tell when it has captured it? In a preliminary study, researchers at the Georgia Institute of Technology have found that they can program a robot to understand when it gains a human's attention and when it falls short. The research is being presented today at the Human-Robot Interaction conference in Lausanne, Switzerland.
"The primary focus was trying to give Simon, our robot, the ...
Earth: Alive -- bacteria back from the brink
2011-03-09
Alexandria, VA – In 1993, "Jurassic Park" thrilled the world with the idea that dinosaurs could be resurrected from bits of DNA preserved in mosquitoes trapped in ancient amber. In the 18 years since the movie came out, scientists have been finding that parts of this scenario are closer to reality than anyone ever imagined: Researchers have found microbes living for tens of thousands - and maybe millions - of years inside salt crystals.
These findings raise exciting questions, as EARTH explores in "Bacteria Back From the Brink" in the April issue. Could these hibernating ...
Eating disorders and body dissatisfaction is double in Muslim teenagers than in Christian
2011-03-09
This release is available in Spanish and French.
The incidence of eating disorders was found to be 2.3-fold higher among Muslim adolescents than among their Christian classmates. Similarly, body dissatisfaction was 1.8-fold higher in the former group. Finally, as a general conclusion, an average of one in four adolescents suffers some type of eating disorder, and 15% suffers body dissatisfaction. These were the conclusions drawn of a research conducted at the University of Granada.
The sample was taken from a Spanish multicultural city, Ceuta, where different religious ...
Migrating moths and songbirds travel at similar rates
2011-03-09
A study published today (09 March) in Proceedings of the Royal Society B by researchers at Rothamsted Research (an institute of the Biotechnology and Biological Sciences Research Council), and the universities of Lund (Sweden), Greenwich and York, reports the surprising finding that night-flying moths are able to match their songbird counterparts for travel speed and direction during their annual migrations but they use quite different strategies to do so - information that adds to our understanding of the lifestyle of such insects, which are important for maintaining ...
University of South Florida researchers find blood-brain barrier damaged by disease
2011-03-09
A study into the effects of Sanfilippo Syndrome type B (MPS III B) has found that the barrier responsible for protecting the brain from the entry of harmful blood-borne substances is structurally and functionally damaged by the devastating disease. University of South Florida researchers identified damage in specific brain structures involved in the pathology of MPS III B, one of four Sanfilippo syndromes, all of which are inherited diseases of metabolism.
The study, using a mouse model of MPS III B, has been published online in the journal PLoS One. Before this study, ...
Cancer in HIV-positive patients
2011-03-09
Most HIV-positive patients die of cancer. In the latest issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2011; 108[8]: 117), Manfred Hensel's research group presents epidemiological data.
The authors surveyed all German hospital outpatient clinics and ambulatory care centers specializing in the treatment of HIV patients in the period from 2000 to 2007 and were thus able to analyze the largest collection of data on the incidence of cancer in HIV patients ever assembled in Germany. It first became clear in the early 1980s that HIV infection is associated ...
Boston researchers create 'SMArt' platform architecture, launch $5,000 health app competition
2011-03-09
Boston, Mass. – Through a grant from the Office of the National Coordinator for Health Information Technology (ONC), researchers at Children's Hospital Boston and Harvard Medical School have developed a first-of-its kind platform architecture to support a flexible health information technology (IT) environment and promote innovation. The SMArt (Substitutable Medical Applications, reusable technologies) platform and interface are being made publicly available today to kick off the start of a $5,000 competition challenging developers to create web applications that provide ...